Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 1
68
Views
1
CrossRef citations to date
0
Altmetric
Original Research: Cardiology

Association between rates of ischemic stroke and all-cause mortality with the Watchman device compared to warfarin and direct oral anticoagulants in patients with atrial fibrillation

, BSORCID Icon & , MD
Pages 1-5 | Received 14 Mar 2023, Accepted 01 Oct 2023, Published online: 19 Oct 2023

  • Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge [published correction appears in Int J Stroke. 2020 Jan 28;:1747493020905964]. Int J Stroke. 2021;16(2):217–221. doi:10.1177/1747493019897870.
  • Tanaka Y, Shah NS, Passman R, Greenland P, Lloyd-Jones DM, Khan SS. Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018. JAHA. 2021;10(15):e020163. doi:10.1161/JAHA.120.020163.
  • Lee E, Choi EK, Han KD, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS One. 2018;13(12):e0209687. doi:10.1371/journal.pone.0209687.
  • Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501–1517. doi:10.1161/CIRCRESAHA.117.309732.
  • Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574–582. doi:10.1093/ehjqcco/qcaa061.
  • Alshehri AM. Stroke in atrial fibrillation: review of risk stratification and preventive therapy. J Family Community Med. 2019;26(2):92–97. doi:10.4103/jfcm.JFCM_99_18.
  • National Guideline Centre (UK). Tools to Predict Stroke in People with Atrial Fibrillation: Atrial Fibrillation: Diagnosis and Management: Evidence Reviews C and D. London: National Institute for Health and Care Excellence (NICE); 2021.
  • Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013;10(3):258–266. doi:10.3969/j.issn.1671-5411.2013.03.004.
  • Parsons C, Patel SI, Cha S, et al. CHA2DS2-VASc score: a predictor of thromboembolic events and mortality in patients with an implantable monitoring device without atrial fibrillation. Mayo Clin Proc. 2017;92(3):360–369. doi:10.1016/j.mayocp.2016.10.008.
  • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi:10.7326/0003-4819-146-12-200706190-00007.
  • Waksman R, Pendyala LK. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy. Am J Cardiol. 2015;115(3):378–384. doi:10.1016/j.amjcard.2014.11.011.
  • Osmancik P, Herman D, Neuzil P, PRAGUE-17 Trial Investigators, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122–3135. doi:10.1016/j.jacc.2020.04.067.
  • Sandhu O, Aftab Z, Anthony AT, Rahmat S, Khan S. Comparison between oral anticoagulation and left atrial appendage occlusion in the prevention of stroke with regard to non-valvular atrial fibrillation. Cureus. 2020;12(9):e10437. doi:10.7759/cureus.10437.
  • Reddy VY, Sievert H, Halperin J, PROTECT AF Steering Committee and Investigators, et al. Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. doi:10.1001/jama.2014.15192.
  • Majule DN, Jing C, Rutahoile WM, Shonyela FS. The efficacy and safety of the WATCHMAN device in LAA occlusion in patients with non-valvular atrial fibrillation contraindicated to oral anticoagulation: a focused review. Ann Thorac Cardiovasc Surg. 2018;24(6):271–278. doi:10.5761/atcs.ra.18-00014.
  • Kubo S, Mizutani Y, Meemook K, Nakajima Y, Hussaini A, Kar S. Incidence, characteristics, and clinical course of device-related thrombus after Watchman left atrial appendage occlusion device implantation in atrial fibrillation patients. JACC Clin Electrophysiol. 2017;3(12):1380–1386. doi:10.1016/j.jacep.2017.05.006.
  • Dukkipati SR, Kar S, Holmes DR, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874–885. doi:10.1161/CIRCULATIONAHA.118.035090.
  • Magdi M, Renjithal SLM, Mubasher M, et al. The WATCHMAN device and post-implantation anticoagulation management. A review of key studies and the risk of device-related thrombosis. Am J Cardiovasc Dis. 2021;11(6):714–722.
  • Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2015;10(9):1109–1125. doi:10.4244/EIJY14M08_18.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.